Total Payments
$1,169
2024 Payments
$249.75
Companies
21
Transactions
39
Medicare Patients
2,085
Medicare Billing
$404,879
Payment Breakdown by Category
Food & Beverage$1,097 (93.9%)
Education$71.63 (6.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,097 | 37 | 93.9% |
| Education | $71.63 | 2 | 6.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $396.85 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $136.57 | 3 | $0 (2024) |
| Pharmacosmos Therapeutics Inc. | $123.48 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $70.91 | 4 | $0 (2022) |
| PUMA BIOTECHNOLOGY, INC. | $68.92 | 3 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $45.41 | 1 | $0 (2022) |
| Seagen Inc. | $39.75 | 2 | $0 (2022) |
| Genentech USA, Inc. | $35.74 | 2 | $0 (2023) |
| Medtronic, Inc. | $34.31 | 2 | $0 (2024) |
| PFIZER INC. | $29.76 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $249.75 | 4 | E.R. Squibb & Sons, L.L.C. ($106.99) |
| 2023 | $218.65 | 6 | Pharmacosmos Therapeutics Inc. ($123.48) |
| 2022 | $170.26 | 7 | PUMA BIOTECHNOLOGY, INC. ($47.50) |
| 2021 | $86.45 | 5 | PUMA BIOTECHNOLOGY, INC. ($21.42) |
| 2020 | $340.36 | 10 | AstraZeneca Pharmaceuticals LP ($237.12) |
| 2019 | $103.03 | 7 | Novartis Pharmaceuticals Corporation ($18.79) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $20.26 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $105.20 | General |
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $106.99 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 08/31/2023 | Genentech USA, Inc. | Alecensa (Biological), Avastin, Gavreto | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: BioOncology | ||||||
| 08/29/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.44 | General |
| Category: Oncology | ||||||
| 07/20/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 03/16/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $123.48 | General |
| Category: HEMATOLOGY | ||||||
| 03/02/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Oncology | ||||||
| 02/09/2023 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Oncology | ||||||
| 12/13/2022 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 11/02/2022 | Alexion Pharmaceuticals, Inc. | — | Education | In-kind items and services | $45.41 | General |
| 10/18/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Seagen Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $26.22 | General |
| Category: Oncology | ||||||
| 05/03/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2021 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Oncology | ||||||
| 10/06/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2021 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Oncology | ||||||
| 05/14/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $116.40 | General |
| Category: Oncology | ||||||
| 06/30/2020 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: Oncology | ||||||
| 05/12/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 484 | 1,048 | $354,732 | $89,312 |
| 2022 | 7 | 498 | 1,011 | $265,413 | $86,059 |
| 2021 | 8 | 545 | 1,150 | $315,201 | $107,189 |
| 2020 | 9 | 558 | 1,384 | $367,617 | $122,319 |
Total Patients
2,085
Total Services
4,593
Medicare Billing
$404,879
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 86 | 420 | $160,294 | $43,361 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 170 | 329 | $88,805 | $21,378 | 24.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 79 | 88 | $50,336 | $10,902 | 21.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 97 | $20,079 | $5,545 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $20,759 | $4,389 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 46 | $8,222 | $1,951 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 21 | $6,237 | $1,786 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 77 | 345 | $99,154 | $35,705 | 36.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 172 | 337 | $60,740 | $22,360 | 36.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 79 | 86 | $49,192 | $12,272 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 65 | 65 | $22,889 | $6,131 | 26.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 48 | 98 | $20,286 | $5,093 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 32 | $9,504 | $2,368 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 48 | $3,648 | $2,131 | 58.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 105 | 485 | $139,890 | $52,049 | 37.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 173 | 322 | $58,055 | $22,095 | 38.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 81 | 86 | $49,192 | $13,046 | 26.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 64 | 64 | $22,400 | $6,285 | 28.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 110 | $22,770 | $6,145 | 27.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $10,972 | $3,718 | 33.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 34 | $10,098 | $2,759 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 24 | $1,824 | $1,091 | 59.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 92 | 470 | $138,365 | $40,672 | 29.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 178 | 422 | $84,295 | $24,233 | 28.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 29 | 150 | $24,000 | $23,770 | 99.0% |
About Dr. Radhika Thorn, MD
Dr. Radhika Thorn, MD is a Hematology & Oncology healthcare provider based in Midlothian, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1871754028.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Radhika Thorn, MD has received a total of $1,169 in payments from pharmaceutical and medical device companies, with $249.75 received in 2024. These payments were reported across 39 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,097).
As a Medicare-enrolled provider, Thorn has provided services to 2,085 Medicare beneficiaries, totaling 4,593 services with total Medicare billing of $404,879. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Student in an Organized Health Care Education/Training Program, Hematology & Oncology
- Location Midlothian, VA
- Active Since 06/20/2008
- Last Updated 08/31/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1871754028
Products in Payments
- TAGRISSO (Drug) $198.00
- MONOFERRIC (Drug) $123.48
- ABECMA (Biological) $106.99
- NERLYNX (Drug) $68.92
- CALQUENCE (Drug) $56.73
- OSTEOCOOL RF ABLATION SYSTEM (Device) $34.31
- PIQRAY (Drug) $34.12
- IBRANCE (Drug) $29.76
- OPDIVO (Biological) $29.58
- ADCETRIS (Biological) $26.22
- Alecensa (Biological) $24.47
- FASLODEX (Drug) $20.86
- clonoSEQ (Device) $20.26
- MEKINIST (Drug) $18.79
- KISQALI (Drug) $18.00
- SARCLISA (Biological) $17.72
- BLENREP (Biological) $17.44
- FOUNDATIONONE (Device) $16.73
- LYNPARZA (Drug) $16.06
- Beleodaq (Drug) $16.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.